01 September 2016
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the acquisition of VRL Laboratories (“VRL”), one of the leading laboratories in pre-transplant testing for the eligibility determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in the US.
Founded in 2010, VRL has become a reference laboratory solely focused on donor eligibility testing and microbiology testing for the transplant and medical communities. The company offers a broad menu of infectious disease screening assays to support the FDA’s21 CFR 1271[1] donor eligibility determination testing requirements, specifically for eye, tissue, organ, stem cell and cord blood, as well as reproductive tissues. VRL employs a total of 60 staff across its main facility in Denver CO, and its satellite laboratories in Boston, MA, Dallas, TX, and Atlanta, GA.
The acquisition of VRL reinforces Eurofins’ footprint in specialty clinical testing services and consolidates the Group’s leadership in the transplantation testing market. Furthermore, VRL’s microbiology testing services expands Eurofins’ testing portfolio and increases client penetration in the transplantation testing market. In return, VRL will have access to the Group’s clients and competencies, as well as its laboratory network infrastructure, which should support its further development.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of VRL is another demonstration of our strategy of expanding and strengthening our network of competence centers. In combination with ViraCor and Diatherix, VRL reinforces the Group’s footprint in the testing market for transplantation and infectious diseases.”
For more information, please visit www.eurofins.com or contact:
Eurofins – a global leader in bio-analysis
Eurofins believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics and discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the significant emerging players in specialty clinical diagnostic testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.
[1] FDA Code of Federal Regulations #21: Human cells, tissues and cellular and tissue-based products